Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Turn Therapeutics is refining the Stage 2 design for GX-03 after early atopic dermatitis data showed rapid eczema responses alongside a notable vehicle effect. Representative image.
Pharma & Biotech

Turn Therapeutics moves to refine GX-03 as the atopic dermatitis evidence bar rises

Explore how Turn Therapeutics is refining the GX-03 Phase 2 trial after rapid eczema responses and a strong vehicle effect. Read what comes next.

Read More
Pharma & Biotech

Can Vertex turn its $10bn Crinetics deal into a rare endocrinology powerhouse?

Discover why Vertex is paying $10 billion for Crinetics and how Palsonify and atumelnant could reshape rare endocrine treatment.

Read More
Pharma & Biotech

Ascletis advances once-monthly ASC36 and ASC36_35 obesity injections into FDA review

Discover why Ascletis’ monthly ASC36 and ASC36_35 obesity drugs matter, and which clinical risks could determine their future.

Read More
Representative image of radiopharmaceutical preparation and PET imaging, illustrating how the Sanyou Bio and Baiyunshan Xihe collaboration aims to combine AI-led antibody discovery with nuclear medicine development for precision oncology.
Medical Devices & Diagnostics

AI meets nuclear medicine as Sanyou Bio and Baiyunshan Xihe pursue cancer diagnostics

Explore how Sanyou Bio and Baiyunshan Xihe are combining AI discovery and nuclear medicine to advance precision oncology theranostics.

Read More
Representative image: Laboratory researchers handle blood samples during chronic hepatitis B drug development, reflecting Brii Bio’s Phase 2b ENRICH and ENHANCE results for BRII-179, elebsiran and pegylated interferon alfa.
Pharma & Biotech

Why Brii Bio’s BRII-179 sequencing data could reshape hepatitis B combination treatment

See how Brii Bio’s Phase 2b hepatitis B data support BRII-179 immune priming while durability and Phase 3 risks remain.

Read More
Representative image: A nuclear medicine clinician monitors intravenous radiopharmaceutical administration, reflecting Radnostix’s acquisition of Lucerno Dynamics assets and its expansion into real-time extravasation monitoring, dosimetry and radioligand therapy workflows.
Medical Devices & Diagnostics

Lucerno Dynamics asset deal gives Radnostix new route into nuclear medicine workflows

Discover how Radnostix’s Lucerno Dynamics deal could reshape radiopharmaceutical monitoring, dosimetry and theranostics delivery.

Read More
Medical Devices & Diagnostics

Butterfly Network enters Brazil with iQ+ and iQ3 handheld ultrasound systems

Discover how Butterfly Network’s Brazil launch could reshape point-of-care ultrasound access, adoption and competition across Latin America.

Read More
Medical Devices & Diagnostics

Endologix DETOUR2 three-year data strengthen case for percutaneous bypass in complex SFA disease

Read how Endologix DETOUR2 three-year data could reshape complex SFA disease treatment while durability and adoption questions remain.

Read More
Pharma & Biotech

Why Permeasis MTD4 could reshape enzyme replacement and intracellular drug discovery

Discover how Permeasis Therapeutics’ MTD4 platform delivers functional proteins inside cells, and the risks that remain before clinical testing.

Read More
Representative image: Oliva Therapeutics’ Amerithroid launch expands the U.S. market for natural T3 and T4 thyroid hormone replacement as regulatory scrutiny intensifies.
Pharma & Biotech

Oliva Therapeutics targets thyroid treatment demand with U.S.-made Amerithroid tablets

Discover how Oliva Therapeutics’ Amerithroid launch expands thyroid treatment choices while facing major FDA and clinical questions.

Read More